Epintek, a Leading Chinese Medical Device CRO, Completes Tens of Millions of Yuan Series C3 Financing and Files for IPO

VCBeat has learned that in August, EPIN (Guiyang) Quality Technology Co., Ltd. (“EPIN Tech”) announced the completion of its C3 round of financing, amounting to tens of millions of yuan. This round was solely invested by Shiyue Capital, with Huangfeng Capital serving as the exclusive financial advisor. The funds will be used to further expand EPIN’s multidisciplinary laboratory capabilities and accelerate the release of production capacity at its already operational laboratories.

Epintek is a medical device technology service platform with investment backing from the Guizhou Provincial Government. Focusing on the rapidly developing medical device and biopharmaceutical industries, the company provides integrated, one-stop services to domestic and international R&D manufacturers and research institutes, covering companion R&D, process validation, preclinical studies, testing and inspection, clinical trials, and regulatory registration. Epintek’s operational center is located in the Hongqiao Business District of Shanghai; its biomedical laboratories are in Wujiang District, Suzhou; its electrical medical and wireless communication laboratories are in Suzhou Industrial Park; its consumables testing center, large animal experimentation and surgical training center, and South China Biomedical R&D and Testing Center are in Baiyun District, Guiyang; and its Research and Testing Center for High-Value Medical Consumables and Biomaterials is located in the High-Tech Zone of Hefei.

EPIN Technology Laboratories is one of the few asset-heavy contract research organization (CRO) laboratories in China. The total area of its operational laboratories exceeds 40,000 square meters. All facilities have obtained national-level CMA and CNAS accreditations, as well as international certifications such as A2LA and IAS from the United States. Its biological laboratories are capable of operating under the FDA Good Laboratory Practice (GLP) system. The company provides rigorous, scientifically sound R&D outsourcing services and testing reports for the Chinese, U.S., and European markets.

EPIN Technology currently provides clients with comprehensive scientific research and testing services, including electromagnetic compatibility (EMC), electrical safety, electrical performance, integrated biocompatibility and pathological studies, microbiology and infection control, chemical analysis and materials research, biomechanics, sterile barrier system studies, physical properties of consumables, preclinical large animal experimental studies, surgical training, and standardized residency training. To date, EPIN has served over 4,000 medical device R&D and innovative enterprises, covering the full spectrum of medical device categories such as electronic medical devices, orthopedics, implants and interventional products, biomedical materials, sterile consumables, in vitro diagnostics (IVD), and software. Currently, EPIN Technology has established a “3+N” technical service and marketing layout centered around major domestic medical device industry clusters. With three central laboratories located in Suzhou, Guiyang, and Hefei, and regional sales centers in Shanghai, Tianjin, Guangzhou, Hangzhou, Nanjing, Changzhou, Nantong, Chengdu, Chongqing, Wuhan, Zhengzhou, Xi’an, and other regions, EPIN delivers comprehensive and timely localized technical services. This network enables rapid response to corporate innovation needs, significantly reducing R&D risks and costs while enhancing R&D efficiency and shortening product time-to-market.

Yu Rui, Chairman of EPIN TechnologyEPIN Technologies expresses its gratitude to October Capital for its recognition and support. With the steadfast backing of both new and existing shareholders, EPIN Technologies will resolutely advance its comprehensive layout of asset-heavy, multi-disciplinary, nationwide, and vertically integrated life health R&D outsourcing laboratories, thereby facilitating high-level innovation in medical device enterprises. In a double celebration, EPIN’s Hefei Implantable Intervention and Biomaterials Laboratory has simultaneously completed its national-level CMA scope expansion, with formal approval granted for its dental testing qualifications. The Hefei laboratory’s testing scope now covers full-item testing for implant-grade raw materials, spinal internal fixation systems, interbody fusion cages, staplers, trocars, dentures, and orthodontic appliances. It provides commissioned and registration testing services supporting regulatory submissions in China, the United States, and Europe, accelerating the domestic and international market launch of products.

Gong Hanting, Founding Partner of October CapitalEPIN Technology is an outstanding medical device CRO company. It has established a full-service portfolio encompassing laboratory testing and research, large and small animal studies, clinical research CRO services, and regulatory registration consulting, with fully accredited laboratories located across China. Medical devices have always been a key focus area for Shiyue Capital. Following our investment in EPIN, we believe that both parties will forge deeper collaboration and complementarity, and we are optimistic about EPIN’s continued empowerment of innovative research in the global medical device industry.

Shiyue Capital is a rapidly growing, emerging private equity investment management firm founded by former senior executives of leading Chinese securities firms and core members of their equity investment and investment banking teams. Shiyue Capital operates three management platforms, with assets under management exceeding RMB 5 billion. Since 2016, it has invested in more than 80 projects, with nearly 30 portfolio companies successfully listed on China’s A-share market and close to 10 projects having filed for initial public offerings (IPOs).